Thread Reader

Yunlong Richard Cao

@yunlong_cao

Sep 23

4 tweets
Twitter

Updating information regarding convergent variants BA.2.3.20, BN.1, BA.2.10.4, BN.2.1, BA.4.6.1, BQ.1, BQ.1.1. In short, BA.2.75.2 and BQ.1.1 are the most antibody-evasive convergent variants tested, far exceeding BA.5 and approaching SARS-CoV-1 level. (1/4)

Yunlong Richard Cao

@yunlong_cao

Sep 16View on Twitter

Sharing our investigation on the unprecedented convergent RBD evolution of BA.2.75 and BA.5 on sites including 346, 356, 444-446, 450, 460, 486, which have generated highly concerning variants such as BA.2.75.2, BR.1, BJ.1, and BQ.1.1. (1/n) biorxiv.org/content/10.110…

Continuous evolution of Omicron has led to numerous subvariants that exhibits growth advantage over BA.5. Such rapid and simultaneous emergence of variants with enormous advantages is unprecedented....

biorxiv.org/content/10.110…

Imprinted SARS-CoV-2 humoral immunity induces converging Omicron RBD evolution

Continuous evolution of Omicron has led to numerous subvariants that exhibits growth advantage over BA.5. Such rapid and simultaneous emergence of variants with enormous advantages is unprecedented....

Show this thread

BA.2.75.2 is slightly more evasive than BQ.1.1 against plasma from BA.2/BA.5 breakthrough infections. Its due to the enriched NTD-NAbs elicited by BA.2/BA.5 infections, which BQ.1.1 can't escape. Note that these varaints are approaching SARS-CoV-1 level escaping capability. (2/4)

As expected, BQ.1.1 escapes Evusheld and bebtelovimab, making all clinically available antibody drugs ineffective. BQ.1.1 and BA.2.75.2 both displayed sufficient hACE2 binding capability. (3/4)

We should be able to update information on BU.1, BR.2, BM.1.1.1, CA.1, and XBB within two weeks. I agree with @Cornelius Roemer that XBB will be the most immune-evasive convergent variant for now, since it should be able to escape the majority of both NTD/RBD NAbs. (4/4)

Yunlong Richard Cao

@yunlong_cao

Biochemistry & Immunology | Host Immune Response, Antibody Drug & Vaccine Design | Assistant Professor at BIOPIC, Peking University

Follow on Twitter

Missing some tweets in this thread? Or failed to load images or videos? You can try to .